The Journal of Urology
Volume 184, Issue 3 , Pages 859-864 , September 2010

Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell Carcinoma

  • Nicholas J. Hellenthal

      Affiliations

    • Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Willie Underwood

      Affiliations

    • Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Remedios Penetrante

      Affiliations

    • Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Alan Litwin

      Affiliations

    • Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Shaozeng Zhang

      Affiliations

    • Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Gregory E. Wilding

      Affiliations

    • Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Bin T. Teh

      Affiliations

    • Van Andel Institute, Grand Rapids, Michigan
    • ,
  • Hyung L. Kim

      Affiliations

    • Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
    • Division of Urology, Cedars-Sinai Medical Center, Los Angeles, California
    • Corresponding Author InformationCorrespondence and requests for reprints: Department of Urology, Cedars Sinai Medical Center, 8635 West Third St., Suite 1070 West, Los Angeles, California 90048 (telephone: 310-423-4700; FAX: 310-423-4711)
    • Financial interest and/or other relationship with Pfizer.

Received 12 January 2010

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225
  2. Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331
  3. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167:57
  4. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. 1994;12:206
  5. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16
  6. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516
  7. Dutcher J, Atkins MB, Margolin K, et al. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II (Management of IL-2 toxicity and studies with other cytokines). Med Oncol. 2001;18:209
  8. Haas NB, Uzzo R. Adjuvant therapy for renal cell carcinoma. Curr Oncol Rep. 2008;10:245
  9. Kim HL, Shah SK, Tan W, et al. Estimation and prediction of renal function in patients with renal tumor. J Urol. 2009;181:2451
  10. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4076
  11. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207
  12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205
  13. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753
  14. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180:94
  15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115
  16. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14:2431
  17. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104:511

 Supplementary material for this article can be obtained at http://www.csmc.edu/rcc.

 Study received institutional review board approval.

 Supported by Pfizer (HLK) and National Institutes of Health R01CA133072-01.

 For another article on a related topic see page 1166.

PII: S0022-5347(10)03560-3

doi: 10.1016/j.juro.2010.05.041

The Journal of Urology
Volume 184, Issue 3 , Pages 859-864 , September 2010

Article Tools

* Image Usage & Resolution